Nektar Therapeutic Systems (NKTR) Com Stk Nil Par Value (CDI)

Sell:$0.63Buy:$0.64$0.04 (6.28%)

Prices delayed by at least 15 minutes
Sell:$0.63
Buy:$0.64
Change:$0.04 (6.28%)
Prices delayed by at least 15 minutes
Sell:$0.63
Buy:$0.64
Change:$0.04 (6.28%)
Prices delayed by at least 15 minutes

Company Information

About this company

Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.

Key people

Howard W. Robin
President, Chief Executive Officer, Director
Sandra A. Gardiner
Interim Chief Financial Officer
Mark A. Wilson
Senior Vice President, Chief Legal Officer
Jonathan Zalevsky
Chief Research and Development Officer
Robert B. Chess
Independent Chairman of the Board
Roy A. Whitfield
Lead Independent Director
Jeffrey Robert Ajer
Independent Director
Diana M. Brainard
Independent Director
Myriam J. Curet
Independent Director
Click to see more

Key facts

  • EPIC
    NKTR
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US6402681083
  • Market cap
    $126.55m
  • Employees
    61
  • Shares in issue
    194.39m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.